Boji Medical TechnologyLtd Valuation
Is 300404 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300404 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300404 (CN¥8.92) is trading above our estimate of fair value (CN¥0.31)
Significantly Below Fair Value: 300404 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300404?
Key metric: As 300404 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 300404's PE Ratio? | |
|---|---|
| PE Ratio | 75.9x |
| Earnings | CN¥44.59m |
| Market Cap | CN¥3.30b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.1x |
| Enterprise Value/EBITDA | 84.6x |
| PEG Ratio | 1.9x |
Price to Earnings Ratio vs Peers
How does 300404's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 22.3x | ||
688621 Beijing Sun-Novo Pharmaceutical Research | 20.6x | 29.5% | CN¥4.6b |
301520 Anhui Wanbang Pharmaceutical TechnologyLtd | 25.5x | n/a | CN¥2.7b |
301096 Hangzhou Bio-Sincerity Pharma-TechLtd | 20.5x | 33.3% | CN¥4.3b |
301257 SMO ClinPlusLTD | 22.6x | 23.2% | CN¥2.3b |
300404 Boji Medical TechnologyLtd | 75.9x | 39.2% | CN¥3.3b |
Price-To-Earnings vs Peers: 300404 is expensive based on its Price-To-Earnings Ratio (75.9x) compared to the peer average (22.3x).
Price to Earnings Ratio vs Industry
How does 300404's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 300404 is expensive based on its Price-To-Earnings Ratio (75.9x) compared to the Asian Life Sciences industry average (31.4x).
Price to Earnings Ratio vs Fair Ratio
What is 300404's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 75.9x |
| Fair PE Ratio | 31.6x |
Price-To-Earnings vs Fair Ratio: 300404 is expensive based on its Price-To-Earnings Ratio (75.9x) compared to the estimated Fair Price-To-Earnings Ratio (31.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sichuan Kelun Pharmaceutical
CN¥48.4b
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.
2422
CN¥30.51
7D
2.2%
1Y
7.6%
Dong-E-E-JiaoLtd
CN¥36.4b
Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.
423
CN¥56.59
7D
-2.4%
1Y
12.8%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.4b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥20.91
7D
-1.8%
1Y
14.6%